title: Effects of probenecid on the pharmacokinetics and pharmacodynamics of adinazolam in humans.
abstract: The effects of probenecid (2 gm) on the pharmacokinetics, pharmacodynamics, and uricosuric effects of adinazolam and N-desmethyladinazolam were assessed after single dose administration of adinazolam mesylate sustained-release tablets (60 mg) in a randomized, four-way crossover, double-blind study involving 16 healthy male volunteers. Probenecid decreased adinazolam oral clearance, renal N-desmethyladinazolam clearance, and the amount of N-desmethyladinazolam excreted in the urine. Probenecid increased the N-desmethyladinazolam/adinazolam AUC ratio, adinazolam maximum concentration (Cmax), N-desmethyladinazolam Cmax, and N-desmethyladinazolam time to reach Cmax. Uric acid renal clearance was increased significantly by adinazolam or probenecid administration compared with placebo; however, coadministration of adinazolam plus probenecid had no additive effect on uric acid clearance. Psychomotor performance was decreased in the adinazolam plus probenecid treatment compared with the adinazolam treatment. Probenecid potentiated the psychomotor effects of adinazolam after coadministration of the compounds, predominantly because of alterations in N-desmethyladinazolam pharmacokinetics. Therefore the adinazolam dose may need to be reduced when coadministered with probenecid.
authors.affiliation: Division of Pharmaceutics, School of Pharmacy, University of North Carolina at Chapel Hill 27599-7360.
authors.forename: P L
authors.initials: PL
authors.lastname: Golden
authors.forename: P E
authors.initials: PE
authors.lastname: Warner
authors.forename: J C
authors.initials: JC
authors.lastname: Fleishaker
authors.forename: R C
authors.initials: RC
authors.lastname: Jewell
authors.forename: S
authors.initials: S
authors.lastname: Millikin
authors.forename: J
authors.initials: J
authors.lastname: Lyon
authors.forename: K L
authors.initials: KL
authors.lastname: Brouwer
mesh_terms: D000284:Administration, Oral; D000328:Adult; D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D001569:Benzodiazepines / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000494:pharmacology*; D004311:Double-Blind Method; D004347:Drug Interactions; D004357:Drug Synergism; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008297:Male; D008570:Memory, Short-Term / Q000187:drug effects; D011339:Probenecid / Q000008:administration & dosage / Q000494:pharmacology*; D011597:Psychomotor Performance / Q000187:drug effects; D014527:Uric Acid / Q000378:metabolism
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D001569:Benzodiazepines; D014527:Uric Acid; C039668:adinazolam; C050132:mono-N-demethyladinazolam; D011339:Probenecid